Hong Kong Local Responsible Person

Companies seeking to sell their medical devices in Hong Kong or IVD products to Hong Kong public hospitals must be listed in the MDACS (Medical Device Administrative Control System) database to meet procurement preference criteria.

Only a Local Responsible Person (LRP), which must be a registered Hong Kong entity, can handle the Listing application and perform various responsibilities such as managing regulatory obligations.

In addition, the Local Responsible Person has responsibility for post-market surveillance (PMS) such as adverse event reporting and ensures labeling compliance. Having an independent third party as an LRP can provide more control over the registration process and greater flexibility in managing distributors. Local Responsible Persons can also facilitate procurement processes for public hospitals, as MDACS-listed products receive preference.

Companies must apply for various classifications and registrations to ensure compliance with local health authorities and market readiness.

Conformity assessment body
Public health

Can I Change My Hong Kong Local Responsible Person?

Yes, appointing a new Hong Kong Local Responsible Person is possible. Manufacturers often consider this when dissatisfied with their current agent, especially if the agent is also their distributor. In such cases, appointing an independent LRP like Cisema can provide greater transparency and control. Additionally, the benefits of appointing an independent Local Responsible Person include enhanced flexibility in distribution strategies and improved compliance with regulatory requirements.

Can I Become My Own Local Responsible Person in the Future?

Yes, this is quite common for manufacturers who grow and wish to establish their own operations in Hong Kong. This local company must satisfy the Hong Kong MDD’s regulatory requirements and is legally responsible for compliance during the entire product life cycle - which includes product registration, post market surveillance, and communication with authorities.

Cisema can remain contracted to help with communications and post market surveillance. Some manufacturers may take on this responsibility themselves once their local operations are ready. Handling these tasks in-house allows for better oversight. However, it requires hiring people who understand the regulatory rules in Hong Kong and any changes to them. Having a Local Responsible Person (LRP) to manage these regulatory obligations is crucial for IVD and medical device companies to ensure compliance and smooth operations.

Clinical Development Services 

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Only a Local Responsible Person (LRP), which must be a registered Hong Kong entity, can handle the Listing application and perform various responsibilities such as managing regulatory obligations.

In addition, the Local Responsible Person has responsibility for post-market surveillance (PMS) such as adverse event reporting and ensures labeling compliance. Having an independent third party as an LRP can provide more control over the registration process and greater flexibility in managing distributors. Local Responsible Persons can also facilitate procurement processes for public hospitals, as MDACS-listed products receive preference.

Companies must apply for various classifications and registrations to ensure compliance with local health authorities and market readiness.

Request a Proposal from our Life Sciences Team about Appointing Us as Your Local Responsible Person LRP in Hong Kong

Let Cisema help turn your plans into reality.

Request Proposal

Useful Articles

View More

GBA Connect Scheme: Using Real World Data to Support China NMPA Approval

Discover how leveraging Real World Data generated in the Greater Bay Area can accelerate market entry for medical products in China.

April 15, 2026
GBA Connect Scheme: Using Real World Data to Support China NMPA Approval
GBA Connect Scheme: Using Real World Data to Support China NMPA Approval
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.

Hong Kong Medical Device Registration

We assist you through every step of the Hong Kong Medical Device Listing process, ensuring compliance with Medical Device Division requirements. Expedited pathways are available, and we will determine if those are feasible.

Hong Kong IVD Registration

We support you through every stage of the Hong Kong IVD Listing process. From classification to handling regulatory requirements, we make the process as smooth as possible.

China Medical Device Registration

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Drug Device Combination Products

We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Medical Device PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-market sampling inspections and regular standard changes. Our specialist PMS team means you stay up to date with the many aspects of compliance.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Regulatory Outsourcing

If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

How We’ve Helped Clients with Our Expert Guidance

Read about how we work with clients to find solutions, bringing together deep industry knowledge with leading talent.

View More
April 18, 2026

China Manufacture License Renewal for Level A2 Pressure Vessels

How Cisema Supported Inox Torres Group, S.L. in Successfully Renewing its China Manufacture License (SELO) for Level A2 Pressure Vessels

The China Manufacture License (CML), also known as the SELO license, is a mandatory requirement for manufacturers of pressure equipment intended for the Chinese market. Inox Torres Group, S.L.’s manufacturing site produces high-pressure vessels falling under the Level A2 scope. This license ensures compliance with China’s stringent quality and safety regulations for special equipment.

The Challenge: Managing SELO Complexity for High-Risk Equipment

Renewing a SELO license for Level A2 pressure vessels required careful coordination across regulatory, technical, and cultural dimensions.

  • Navigating Regulatory Complexity
    Navigating the complex and evolving SELO regulatory framework, particularly for high-risk products under Level A2, required meticulous planning and real-time compliance updates.
  • Ensuring Audit Readiness
    Inox Torres Group, S.L. needed to ensure all documentation and procedures were fully up to date and to select an appropriate demo product that met inspection requirements.
  • Managing Inspector Expectations
    Success depended on understanding the unspoken cultural and procedural expectations of SELO inspectors, including hosting and on-site hospitality.

Our Solution: Full-Spectrum SELO Audit Support

Recognizing the high stakes of SELO license renewal, Inox Torres Group, S.L. engaged Cisema for comprehensive regulatory and strategic support.

  • Reviewed the Quality Management System
    Cisema led the review and upgrade of the customer’s quality management system in line with the latest Chinese requirements, including a comprehensive gap analysis and revision of key documentation.
  • Audit Simulation & Preparation
    A preparatory remote audit simulation was conducted, walking through every step of the audit to ensure full readiness ahead of the on-site inspection.
  • Delivered On-Site Bilingual & Regulatory Support
    During the on-site audit, Cisema provided continuous bilingual support, interpreting inspector questions in real time and translating regulatory nuances for the customer.
  • Provided Culturally Appropriate Inspector Hosting
    Cisema arranged culturally appropriate corporate hospitality, helping establish a respectful and positive tone for the inspection. The team remained onsite throughout all audit days, including the weekend, to ensure no detail was overlooked.

The Outcome: Successful Renewal Without Disruption

Through hands-on execution and close coordination, the SELO renewal process was completed smoothly and efficiently.

  • Secured CML Renewal with Full A2 Status
    Inox Torres Group, S.L. successfully renewed its China Manufacture License for pressure vessels, maintaining its Level A2 classification.
  • Executed the Project Efficiently
    Full regulatory preparation and audit execution were completed within six months.
  • Achieved Seamless Inspector Coordination
    SELO inspectors were hosted and coordinated smoothly, with culturally aligned engagement throughout the audit.
  • Secured Regulatory Continuity  
    The renewal avoided operational disruptions and ensured compliance with updated SELO requirements.

Expertise and Efficiency: Acting as an Extension of the Client Team

Cisema’s experienced consultants acted as an extension of Inox Torres Group, S.L.’s regulatory and quality teams, providing both regulatory expertise and strategic foresight. Inspector concerns were anticipated and addressed proactively, transforming a potentially stressful process into a streamlined, well-orchestrated engagement with Chinese authorities.

Hands-on mentoring throughout the project helped the customer gain confidence and clarity in managing future SELO audits.

Why Choose Cisema

  • Strategic Regulatory Expertise: Deep understanding of Chinese bureaucracy, evolving SELO requirements, and inspector expectations.
  • Mentorship & Training: Step-by-step guidance that supported the customer’s quality team throughout the process.
  • Corporate Hospitality Excellence: Culturally aligned hosting that supports successful audit outcomes in China.
  • Audit Readiness & Precision: Gap analysis, audit simulation, and documentation refinement to pass SELO reviews efficiently.
  • End-To-End Support: Full management of the audit process, from document revision to on-site interpretation.

Further Information

Explore Cisema’s China Special Equipment (SELO) Certification services.

Learn More
China Manufacture License Renewal for Level A2 Pressure Vessels
Previous
Previous

Latest Insights

View More

Hong Kong to Regulate Medical Gases as Pharmaceutical Products from June 2026

Learn the registration requirements, scope, and compliance steps as Hong Kong regulates medical gases as pharmaceutical products.

April 15, 2026
Hong Kong to Regulate Medical Gases as Pharmaceutical Products from June 2026

Guangdong MPA Publishes 2025 GBA Connect Scheme Medical Products Catalogue

Guangdong’s MPA and Health Commission issued the 2025 GBA Connect “urgently needed” catalogue covering 115 Hong Kong–Macao drugs and devices.

March 31, 2026
Guangdong MPA Publishes 2025 GBA Connect Scheme Medical Products Catalogue
Previous
Previous

Contact Our Life Sciences Team

And discover how we can support you as your Local Responsible Person in applying for regulatory approval in Hong Kong.

Request Proposal